These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Author: Ziemer M, Wiesend CL, Vetter R, Weiss J, Blaschke S, Norgauer J, Mockenhaupt M.
    Journal: Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936.
    Abstract:
    OBJECTIVE: To assess the type of severe skin reactions caused by valdecoxib treatment. DESIGN: Case registry of severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. SETTING: All hospitals in Germany that treat patients with severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. PATIENTS: Five case notifications of Stevens-Johnson syndrome after the use of valdecoxib were reevaluated following the withdrawal of valdecoxib on April 7, 2005. RESULTS: A thorough review of all reported cases of severe skin reactions caused by valdecoxib revealed extensive erythematous, targetlike skin eruptions in addition to facial edema and dyspnea. Histologic changes, clinical pattern, and outcome demonstrated a distinct disease entity. CONCLUSION: Valdecoxib induces severe skin reactions different from those of Stevens-Johnson syndrome and toxic epidermal necrolysis in clinical and histopathologic findings, course, and outcome.
    [Abstract] [Full Text] [Related] [New Search]